Efficacy has been suggested in ALS, where autologous Treg cells that were expanded in vitro and administered intravenously with concomitant IL-2 slowed progression rates during early and later stages of disease (Thonhoff et al., 2018). The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.